Allogeneic processed thymus tissue

Allogeneic processed thymus tissue, sold under the brand name Rethymic, is a thymus tissue therapy used for immune reconstitution in children with congenital athymia, a rare condition in which patients are born without a functioning thymus gland. It is the first thymus tissue product ever approved by the U.S. Food and Drug Administration, cleared in October 2021 for pediatric patients, and it is administered as a one-time surgical implantation of cultured donor thymus slices into the quadriceps muscle. Reconstitution of protective immunity takes six months to two years, and the product carries a wholesale acquisition cost of 2.81 million U.S. dollars, placing it among the most expensive therapies in the world.同种异体处理胸腺组织（商品名 Rethymic）是一种用于先天性胸腺发育不全儿童免疫重建的胸腺组织疗法，该罕见病患者出生时即没有功能性胸腺。它是首个获美国食品药品监督管理局批准的胸腺组织产品，2021 年 10 月获批用于儿童患者，通过一次性手术将培养的供体胸腺组织片植入股四头肌。保护性免疫的重建需六个月至两年，该产品的批发采购价为 281 万美元，属全球最昂贵的疗法之列。

History and development

• Congenital athymia, the disease Rethymic was developed to treat, arises when the thymus fails to form during embryogenesis, most often as complete DiGeorge anomaly from a 22q11.2 deletion, but also in CHARGE syndrome, FOXN1 deficiency and other syndromic settings. Without a thymus, T lymphocytes cannot undergo maturation, leaving patients with essentially no naive T cells and exposing them to recurrent life-threatening infections. The natural history recorded before the product existed was bleak: in an untreated population observed from 1991 through 2017, two-year survival was only 6 percent, and every patient had died by three years of age. Affected children spend an average of 150 days per year in hospital, a supportive-care burden the sponsor has estimated at 5.5 million dollars over three years.Rethymic 所针对的先天性胸腺发育不全源于胚胎发生期胸腺形成失败，最常见于 22q11.2 缺失导致的完全 DiGeorge 畸形，也见于 CHARGE 综合征、FOXN1 缺乏及其他综合征情形。没有胸腺，T 淋巴细胞便无法成熟，患者几乎没有初始 T 细胞，反复遭受危及生命的感染。该产品出现前记录的自然史十分严峻：在 1991 年至 2017 年观察的未治疗人群中，两年生存率仅 6%，所有患儿三岁前死亡。受累儿童平均每年住院 150 天，申办方估计三年间的支持治疗负担达 550 万美元。
• The therapeutic concept of implanting cultured thymus tissue was developed at Duke University, where Louise Markert's group established a single-center programme that treated 105 children between 1993 and 2020 across ten prospective, open-label studies. Cultured thymus tissue was implanted surgically, and the early experience demonstrated that the graft could establish thymopoiesis in athymic recipients. That body of work, summarised in a 2021 paper in the Journal of Allergy and Clinical Immunology reporting experience with cultured thymus tissue in 105 children, became the evidentiary basis for licensure. The median age at treatment in the programme was nine months, with a range of one to 36 months.植入培养胸腺组织的治疗概念由杜克大学开发，Louise Markert 团队在此建立了单中心项目，1993 年至 2020 年间在十项前瞻性开放标签研究中治疗了 105 名儿童。培养胸腺组织经手术植入，早期经验表明移植物可在胸腺缺失的受者中建立胸腺生成。该成果汇总于 2021 年《过敏与临床免疫学杂志》报告 105 名儿童培养胸腺组织经验的论文，成为获批的证据基础。项目中治疗时的中位年龄为九个月，范围一至 36 个月。^[1]
• The long interval between the 2003 orphan designation and the 2021 approval reflects the difficulty of manufacturing a living tissue product to modern standards rather than any doubt about the biology. Donor thymus tissue is a scarce input: it comes only from infants of a defined age range undergoing cardiac surgery that removes part of the thymus, and each recipient must be size-matched to a donor, so the supply chain is a chain of coincidences rather than a fermentation tank. Scaling that supply while demonstrating consistent potency and sterility was the core regulatory problem, and it is why the label describes a product that is processed and cultured for 13 to 20 days under tightly controlled conditions before it can be released.2003 年孤儿药资格与 2021 年获批之间的漫长间隔，反映的是按现代标准生产活组织产品的困难，而非生物学本身的疑问。供体胸腺组织是稀缺投入：它仅来自接受心脏手术切除部分胸腺的特定年龄婴儿，每位受者都须与供体体型匹配，因此供应链是一连串巧合的链条而非发酵罐。在放大供应的同时证明一致的有效性与无菌性是核心监管问题，这正是标签所描述的产品须在严格受控条件下加工培养 13 至 20 天方可放行的原因。
• Enzyvant Therapeutics GmbH, based in Basel, Switzerland, took the programme forward as RVT-802 and obtained a U.S. orphan drug designation for congenital athymia on 15 August 2003, one of the earliest designations in the modern programme. Development stretched over more than two decades and included a complete response letter from the FDA on manufacturing grounds, which the company had to resolve before approval could be granted. On 8 October 2021 the FDA approved Rethymic for immune reconstitution in pediatric patients with congenital athymia, simultaneously awarding a rare pediatric disease voucher, and granting the company orphan exclusivity running to 8 October 2028. The approval was the first for any thymus tissue product anywhere in the world.总部位于瑞士巴塞尔的 Enzyvant Therapeutics GmbH 以 RVT-802 之名推进该项目，并于 2003 年 8 月 15 日获得美国先天性胸腺发育不全孤儿药资格，是现代孤儿药计划中最早的资格之一。开发历时二十余年，其间曾因生产问题收到 FDA 的完整回复函，公司须先解决该问题方可获批。2021 年 10 月 8 日，FDA 批准 Rethymic 用于先天性胸腺发育不全儿童患者的免疫重建，同时授予罕见儿科疾病券，并给予至 2028 年 10 月 8 日的孤儿药独占期。该批准是全球首个胸腺组织产品获批。
• After approval, Enzyvant operated as a subsidiary of Sumitomo Pharma, and in a September 2024 reorganisation its units were merged into a unified Sumitomo Pharma, with Sumitomo Pharma America now listed as the marketer on the U.S. label. The product remains a single-asset franchise: North American Rethymic sales were reported at 45 million dollars for fiscal 2024, with the company forecasting a similar figure for 2025 and naming expansion of sales as a priority in its annual report. For a therapy treating an ultra-rare disease, those numbers reflect both the price and the very small eligible population, estimated at roughly 17 to 24 affected births per year in the United States.获批后，Enzyvant 作为住友制药的子公司运营，并在 2024 年 9 月的重组中并入统一的住友制药，美国标签上标注的上市方为住友制药美国公司。该产品仍是单资产产品线：北美 Rethymic 2024 财年销售额报告为 4500 万美元，公司预测 2025 年数字相近，并在年报中将扩大销售列为优先事项。对一种治疗超罕见疾病的疗法而言，这些数字既反映了价格，也反映了极小的合格人群——美国估计每年仅约 17 至 24 例受累新生儿。

Medical uses

• The labeled indication is narrow and specific: immune reconstitution in pediatric patients with congenital athymia, and the label explicitly states that Rethymic is not indicated for the treatment of severe combined immunodeficiency. The efficacy population in the ten supporting studies comprised 95 patients with a median treatment age of nine months, of whom 98 percent had complete DiGeorge syndrome, including 38 percent with a chromosome 22q11.2 deletion, 24 percent with CHARGE syndrome and 2 percent with FOXN1 deficiency. Fifty-three percent had typical complete DiGeorge syndrome without a T-cell-related rash, while 44 percent had atypical disease with rash, lymphadenopathy or oligoclonal T cells. Patients without congenital athymia, such as those with SCID, and patients with prior thymus or hematopoietic transplants were excluded from the efficacy analysis.标签适应证狭窄而明确：先天性胸腺发育不全儿童患者的免疫重建，标签明确指出 Rethymic 不适用于治疗严重联合免疫缺陷。十项支持研究中的有效性人群包括 95 例患者，治疗中位年龄九个月，其中 98% 患有完全 DiGeorge 综合征，包括 38% 染色体 22q11.2 缺失、24% CHARGE 综合征与 2% FOXN1 缺乏。53% 为无 T 细胞相关皮疹的典型完全 DiGeorge 综合征，44% 为伴皮疹、淋巴结病或寡克隆 T 细胞的不典型类型。无先天性胸腺发育不全者（如 SCID 患者）以及既往接受胸腺或造血干细胞移植者被排除在有效性分析之外。
• Dosing is patient-customised rather than weight-based: the recommended dose range is 5,000 to 22,000 square millimetres of Rethymic per square metre of recipient body surface area, delivered as slices whose total surface area is measured at the manufacturing facility. The product is administered by a qualified surgical team in a single surgical session at a qualified hospital, implanted into the quadriceps muscle, which must provide a healthy bed of muscle tissue. Because the amount of tissue required scales with the child's size, very young and small recipients need proportionally smaller grafts, and the manufacturing step is coordinated so that the portion representing the minimum dose is identified for the surgical team. Each patient receives a single administration, and the clinical programme contained no repeat dosing or re-implantation data.剂量按患者定制而非按体重计算：推荐剂量范围为每平方米受者体表面积 5,000 至 22,000 平方毫米 Rethymic，以组织片形式给药，其总表面积在生产场所测量。产品由合格外科团队在合格医院单次手术中给药，植入股四头肌，该处须有健康的肌肉床。由于所需组织量随患儿体型缩放，极小受者需要按比例更小的移植物，生产环节经协调向手术团队指明代表最小剂量的部分。每位患者接受单次给药，临床项目不含重复给药或再次植入数据。
• Diagnosis drives entry into treatment and is immunological rather than genetic: the studies required flow-cytographic documentation of fewer than 50 naive T cells per cubic millimetre, defined as CD45RA-positive and CD62L-positive cells, or naive cells below 5 percent of total T cells, with a phytohemagglutinin response assessed to gauge residual function. Although the studies enrolled patients from one month to 16 years of age, the efficacy population skewed young, with a median treatment age of nine months, reflecting that the diagnosis is typically made in infancy. No data exist in adults, and the label's indication is pediatric, so use in grown patients with atypical or partial athymia is outside both the evidence and the authorization.诊断驱动治疗准入，且是免疫学而非遗传学的：研究要求流式细胞术证明每立方毫米初始 T 细胞少于 50 个（定义为 CD45RA 阳性、CD62L 阳性细胞），或初始细胞低于总 T 细胞的 5%，并评估植物血凝素应答以衡量残余功能。尽管研究入组一月至 16 岁患者，有效性人群偏年幼，治疗中位年龄九个月，反映诊断通常在婴儿期作出。无成人数据，标签适应证为儿童，因此用于伴不典型或部分胸腺发育不全的成年患者既在证据之外也在许可之外。
• The pivotal survival findings come from the clinical programme itself: Kaplan-Meier estimated survival was 77 percent at one year, with a 95 percent confidence interval of 0.670 to 0.841, and 76 percent at two years, with a confidence interval of 0.658 to 0.832. Among patients who were alive at one year after treatment, survival was 94 percent at a median follow-up of 10.7 years, indicating that children who clear the first post-implant year can expect durable benefit. The comparison with the untreated natural history, in which two-year survival was 6 percent and all patients died by three years, anchors the clinical value of the procedure.关键生存发现来自临床项目本身：Kaplan-Meier 估计一年生存率为 77%（95% 置信区间 0.670 至 0.841），两年生存率为 76%（置信区间 0.658 至 0.832）。在治疗后一年仍存活的患者中，经中位 10.7 年随访，生存率为 94%，表明度过植入后第一年的儿童可获得持久获益。与未治疗自然史（两年生存率 6%、所有患儿三岁前死亡）的比较，奠定了该手术的临床价值。
• Immunosuppressive therapy is recommended for patients receiving Rethymic, with the regimen selected on the basis of disease phenotype and phytohemagglutinin response. Regimens used in the programme included cyclosporine, titrated to trough levels of 100 to 150 nanograms per millilitre, basiliximab as a single 5 milligram per kilogram intravenous dose, mycophenolate mofetil at 15 milligrams per kilogram per dose every eight hours, and alemtuzumab at 0.25 milligrams per kilogram daily for four days with premedication. Higher cyclosporine targets of 250 to 300 nanograms per millilitre were used for patients with evidence of maternal engraftment or atypical complete DiGeorge syndrome and a phytohemagglutinin response above 40,000 counts per minute on immunosuppression.建议接受 Rethymic 的患者使用免疫抑制治疗，方案依据疾病表型与植物血凝素应答选择。项目中使用的方案包括环孢素（调整至谷浓度 100 至 150 纳克/毫升）、巴利昔单抗单次 5 毫克/千克静脉给药、霉酚酸酯 15 毫克/千克每八小时一次，以及阿仑单抗 0.25 毫克/千克每日一次连用四天并予预用药。对有母体植入证据或伴植物血凝素应答在免疫抑制下超过 40,000 计数/分钟的不典型完全 DiGeorge 综合征患者，环孢素目标谷浓度提高至 250 至 300 纳克/毫升。
• In practice, access is gated by surgical and manufacturing capacity rather than by the label: the procedure requires donor thymus tissue from infants undergoing cardiac surgery, coordinated processing and culture, and a qualified surgical team, and reporting in 2025 identified Duke Children's Hospital as the only facility routinely performing the implantation. The immune reconstitution the label promises is slow, and the label warns that reconstitution sufficient to protect from infection is unlikely to develop before six to 12 months after treatment, so infection-control measures must continue until thymic function is established. Families must therefore plan for a prolonged vulnerable period after the operation.在实践中，可及性受手术与生产能力而非标签限制：该手术需要接受心脏手术婴儿的供体胸腺组织、协调的加工与培养以及合格外科团队，2025 年的报道指出杜克儿童医院是唯一常规开展该植入手术的机构。标签承诺的免疫重建是缓慢的，标签警告足以防护感染的免疫重建不太可能在治疗后六至 12 个月内建立，因此在胸腺功能确立前必须持续感染控制措施。家属须为术后漫长的易感期做准备。

Adverse effects

• The safety profile is defined by the label's list of adverse reactions occurring in at least 10 percent of patients: hypertension at 19 percent, cytokine release syndrome at 18 percent, rash at 15 percent, hypomagnesemia at 16 percent, renal impairment or failure at 12 percent, thrombocytopenia at 12 percent, and graft versus host disease at 10 percent. Hypertension and cytokine release syndrome dominate the early post-implant period, while hypomagnesemia reflects the calcineurin-inhibitor immunosuppression that accompanies the graft. Renal impairment and thrombocytopenia require the scheduled laboratory monitoring set out in the label.安全性特征由标签列出的、发生于至少 10% 患者的不良反应定义：高血压 19%、细胞因子释放综合征 18%、皮疹 15%、低镁血症 16%、肾功能受损或衰竭 12%、血小板减少症 12% 以及移植物抗宿主病 10%。高血压与细胞因子释放综合征主导植入后早期，低镁血症反映伴随移植物的钙调磷酸酶抑制剂免疫抑制。肾功能受损与血小板减少需要标签规定的定期实验室监测。
• Autoimmune phenomena are a distinctive liability of the product: 37 patients, or 35 percent of the clinical programme, experienced autoimmune-related adverse reactions. The most frequent were thrombocytopenia including idiopathic thrombocytopenic purpura in 13 patients, or 12 percent, neutropenia in 9 patients, or 9 percent, proteinuria in 7 patients, or 7 percent, hemolytic anemia in 7 patients, or 7 percent, and alopecia in 4 patients, or 4 percent. Hypothyroidism, autoimmune hepatitis and autoimmune arthritis each occurred in 2 patients, or 2 percent. Single patients, at 1 percent each, experienced transverse myelitis, albinism, hyperthyroidism and ovarian failure.自身免疫现象是该产品的一项独特负担：临床项目中 37 例患者（35%）发生自身免疫相关不良反应。最常见者为 13 例患者（12%）的血小板减少（包括特发性血小板减少性紫癜）、9 例（9%）的中性粒细胞减少、7 例（7%）的蛋白尿、7 例（7%）的溶血性贫血与 4 例（4%）的脱发。甲状腺功能减退、自身免疫性肝炎与自身免疫性关节炎各发生于 2 例患者（2%）。横贯性脊髓炎、白化病、甲状腺功能亢进与卵巢衰竭各 1 例（1%）。
• The onset window for autoimmune events is unusually wide, ranging from three days before the surgical implantation to 16 years after treatment, although most events occurred within the first year. This long tail drives the label's monitoring schedule: complete blood counts with differential weekly for the first two months after treatment and then monthly through 12 months, liver enzymes, serum creatinine and urinalysis monthly for three months and then every three months through 12 months, and thyroid function studies before treatment and at six and 12 months. After the first year, testing is performed as clinically indicated. The breadth of autoimmune events mirrors the breadth of tissues a reconstituted immune system can attack once tolerance is incomplete.自身免疫事件的起病窗口异常宽泛，从手术植入前三天至治疗后 16 年不等，但多数事件发生于第一年内。这一长尾驱动了标签的监测安排：治疗后前两个月每周一次全血细胞计数及分类，随后每月一次至 12 个月；肝酶、血清肌酐与尿液分析前三个月每月一次，随后每三个月一次至 12 个月；甲状腺功能在治疗前及第六、12 个月检查。第一年后按临床指征检测。自身免疫事件的广度反映了重建的免疫系统在耐受不完全时可攻击的组织广度。
• Graft versus host disease, reported in 10 percent of patients, is the complication the immunosuppressive regimens are designed to contain, and the label directs monitoring and prompt treatment of patients at risk. Cytokine release syndrome at 18 percent is managed with standard supportive care and, in severe cases, cytokine blockade, although the label frames it within the post-implant inflammatory response to the establishing graft. Infections remain a background risk in the athymic host until reconstitution is complete, which is why the label's infection-control provisions run for the first six to 12 months. No treatment-related deaths were reported as a defining feature of the programme in the published experience, with the survival data reflecting the underlying disease's lethality rather than product toxicity.移植物抗宿主病见于 10% 的患者，是免疫抑制方案旨在控制的并发症，标签要求监测并及时治疗高风险患者。18% 的细胞因子释放综合征按标准支持治疗处理，严重病例使用细胞因子阻断，标签将其置于植入后移植物建立期间的炎症反应框架内。在重建完成前，感染仍是胸腺缺失受者的背景风险，这正是标签的感染控制条款覆盖前六至 12 个月的原因。在已发表经验中，无治疗相关死亡被列为项目的定义性特征，生存数据反映的是基础疾病的致死性而非产品毒性。
• Beyond the product's own reactions, the procedure carries the ordinary risks of implanting foreign tissue into an infant's muscle, and the label requires a healthy muscle bed in the quadriceps, a single surgical session, and operating-room supply of sterile culture dishes and saline for injection. Because recipients are infants, often with congenital heart disease as part of complete DiGeorge syndrome, perioperative assessment and coordination with cardiac status are part of the practical safety picture. The label's provisions on minimum-dose portions and slice measurement are as much safety measures as dosing rules, ensuring the graft placed in the muscle is the graft whose surface area was verified at release.除产品自身反应外，该手术还带有将异物组织植入婴儿肌肉的常规风险，标签要求股四头肌有健康肌肉床、单次手术，以及手术室提供无菌培养皿与注射用生理盐水。由于受者是婴儿，且常伴先天性心脏病（完全 DiGeorge 综合征的一部分），术前评估与心脏状态的协调是实际安全图景的一部分。标签关于最小剂量部分与组织片测量的条款既是剂量规则也是安全措施，确保植入肌肉的移植物就是放行时验证过表面积的那一份。

Contraindications and interactions

• The label lists no contraindications for Rethymic, an unusual position that reflects both the fatal natural history of congenital athymia and the fact that the product is a surgically implanted tissue rather than a systemically distributed drug. The clinical studies excluded patients with heart surgery anticipated within four weeks before or three months after the planned treatment date, patients with HIV infection, and patients who were not considered good surgical candidates, and those exclusions function as the practical boundary of use. Maternal engraftment or an elevated phytohemagglutinin response marks patients who need intensified immunosuppression rather than exclusion from treatment.Rethymic 的标签未列任何禁忌，这一不寻常的立场既反映了先天性胸腺发育不全的致命自然史，也反映该产品是手术植入的组织而非全身分布药物。临床研究排除了预计在计划治疗日前四周内或后三个月内接受心脏手术的患者、HIV 感染者以及不被视为良好手术候选者的患者，这些排除标准构成实际使用边界。有母体植入或植物血凝素应答升高标记的是需要强化免疫抑制的患者，而非排除治疗的对象。
• No formal drug-interaction studies were conducted, which is unsurprising for a tissue implant whose pharmacology is local and immunological. The interaction landscape is instead defined by the immunosuppressants used to protect the graft: cyclosporine and tacrolimus require renal-function monitoring and have their own interaction profiles, mycophenolate mofetil adds myelosuppression to the thrombocytopenia already caused by the product, and alemtuzumab produces prolonged lymphocyte depletion that overlaps with the slow immune reconstitution the graft is meant to achieve. Concomitant live vaccines are avoided while the patient is immunosuppressed, consistent with the infection-control provisions of the label.未进行正式药物相互作用研究，这对药理作用局部且呈免疫性的组织植入物而言并不意外。相互作用格局反而由保护移植物的免疫抑制剂定义：环孢素与他克莫司需要肾功能监测并有各自的相互作用特征，霉酚酸酯在产品已致血小板减少之外增加骨髓抑制，阿仑单抗造成持久的淋巴细胞清除，与移植物所要实现的缓慢免疫重建相互重叠。免疫抑制期间避免接种活疫苗，与标签的感染控制条款一致。
• The label's warnings and precautions section doubles as the practical management protocol: immune reconstitution sufficient to protect from infection is unlikely before six to 12 months, so infection-control measures apply until thymic function is established, patients at risk of graft versus host disease are monitored and promptly treated, and autoimmune events are tracked through the scheduled blood, renal, hepatic and thyroid testing. There is no dose reduction available if a reaction occurs, since the graft is implanted once, so management is supportive and immunological rather than dose-based. This absence of a dosing lever is characteristic of tissue therapies and shapes every clinical decision after implantation.标签的警告与注意事项一节兼具实际管理规程的作用：足以防护感染的免疫重建不太可能在六至 12 个月前建立，因此在胸腺功能确立前适用感染控制措施，监测并及时治疗有移植物抗宿主病风险的患者，并通过定期血液、肾、肝、甲状腺检测追踪自身免疫事件。若发生反应无法减量，因为移植物只植入一次，故管理是支持性与免疫学的而非基于剂量的。缺少剂量调节杠杆是组织疗法的特征，塑造了植入后的每一个临床决策。

Pharmacology

• The pharmacology of Rethymic is the pharmacology of the thymus itself. The thymus is the organ in which bone-marrow-derived T-cell precursors are educated into self-tolerant, MHC-restricted T lymphocytes, and congenital athymia removes that organ, leaving peripheral blood with fewer than 50 naive T cells per cubic millimetre, the diagnostic threshold used in the clinical studies. The implanted cultured thymus tissue provides the stromal and epithelial environment in which recipient precursors can mature, effectively transplanting the organ's function rather than a molecule. The consequence is a slow, staged reconstitution in which naive T cells appear over months rather than hours.Rethymic 的药理学即胸腺本身的药理学。胸腺是骨髓来源的 T 细胞前体接受教育、成为自身耐受且受 MHC 限制的 T 淋巴细胞的器官，先天性胸腺发育不全切除该器官，使外周血每立方毫米初始 T 细胞少于 50 个，即临床研究使用的诊断阈值。植入的培养胸腺组织提供受体前体成熟的基质与上皮环境，实质上是移植器官的功能而非分子。其结果是分阶段的缓慢重建，初始 T 细胞在数月而非数小时内出现。
• The graft is thymocyte-depleted allogeneic tissue, so the pharmacology includes a window in which donor-derived cells could attack the recipient, which is why graft versus host disease is both a labeled adverse reaction at 10 percent and the target of the immunosuppressive regimens. Conversely, recipients with maternal engraftment or atypical complete DiGeorge syndrome carry pre-existing oligoclonal T cells that can attack the graft, and they receive higher cyclosporine targets. The phytohemagglutinin response, a functional readout of residual T-cell competence, is used to titrate this balance, illustrating how the product's dosing logic is immunological rather than pharmacokinetic.移植物为去胸腺细胞的同种异体组织，因此其药理学包含一个供体来源细胞可能攻击受者的窗口，这正是移植物抗宿主病既是标签不良反应（10%）又是免疫抑制方案目标的原因。反之，有母体植入或不典型完全 DiGeorge 综合征的受者携带既可攻击移植物的既有寡克隆 T 细胞，需接受更高环孢素目标谷浓度。植物血凝素应答作为残余 T 细胞功能的功能读出，被用于校准这一平衡，说明该产品的剂量逻辑是免疫学的而非药代动力学的。
• Time course is the central pharmacodynamic parameter: the label states that immune reconstitution sufficient to protect from infection is unlikely before six to 12 months, and the long-term data show that patients surviving the first year then had 94 percent survival at a median 10.7 years of follow-up. Naive T-cell output, the pharmacodynamic endpoint that matters clinically, is tracked in follow-up through flow cytometry of the same markers used for diagnosis, namely CD45RA-positive, CD62L-positive cells. Unlike small-molecule drugs, there is no half-life, clearance or dose-response curve in the conventional sense, and the product's effect persists for as long as the implanted tissue survives.时程是核心药效学参数：标签指出足以防护感染的免疫重建不太可能在六至 12 个月前建立，长期数据显示度过第一年的患者经中位 10.7 年随访生存率达 94%。具有临床意义的药效学终点初始 T 细胞输出，通过流式细胞术以诊断所用相同标志物（CD45RA 阳性、CD62L 阳性细胞）在随访中追踪。与小分子药物不同，没有常规意义上的半衰期、清除率或剂量反应曲线，产品效应持续的时间与植入组织的存活时间一样长。
• The product's place among immunotherapies is defined by what it replaces. In an athymic host, hematopoietic stem cell transplantation can populate the periphery with mature T cells but cannot restore thymic education, so recipients remain dependent on the grafted repertoire rather than generating their own, which is why the clinical studies excluded patients with prior thymus or hematopoietic transplants. Thymus tissue implantation is the only approach that addresses the missing organ itself, and the survival data indicate that restoring the organ works where transferring cells cannot. That distinction explains both the product's uniqueness and the reason no other class of drug can substitute for it in complete athymia.该产品在免疫疗法中的位置由它所替代的东西定义。在胸腺缺失的受者中，造血干细胞移植可以以外周成熟 T 细胞填充免疫系统，但无法恢复胸腺教育，受者仍依赖移植的受体库而非生成自己的库，这正是临床研究排除既往胸腺或造血干细胞移植患者的原因。胸腺组织植入是唯一针对缺失器官本身的方法，生存数据表明恢复器官在转移细胞无法成功之处有效。这一区分既解释了产品的独特性，也解释了为何没有其他类药物可在完全胸腺发育不全中替代它。

Chemistry

• Rethymic is composed of allogeneic thymocyte-depleted thymus tissue-agdc, supplied with porcine skin gelatin, formalin-treated absorbable gelatin sponge and fetal bovine serum as the implantation matrix. The tissue is yellow to brown and arrives as processed slices of varying thickness and shape, so the dose is a surface area rather than a mass. There is no small-molecule identity: no molecular formula, SMILES or InChIKey applies to the clinical material, and the chemical-identifier fields of a conventional drug entry remain empty for this product. Its identity is defined biologically, by the donor tissue's capacity to support thymopoiesis after implantation.Rethymic 由同种异体、去胸腺细胞的胸腺组织构成，随附猪皮明胶、甲醛处理的可吸收明胶海绵与胎牛血清作为植入基质。组织呈黄至棕色，以不同厚度与形状的加工组织片形式交付，因此剂量是表面积而非质量。它没有小分子身份：临床材料不适用分子式、SMILES 或 InChIKey，常规药物条目的化学标识符字段对该产品留空。其身份由生物学定义，即供体组织在植入后支持胸腺生成的能力。
• Manufacturing begins with donor thymus tissue obtained from healthy infants of a defined age range who have undergone cardiac surgery that removes part of the thymus and who are close in size to the intended recipient. The tissue is then processed and cultured for 13 to 20 days before implantation, a step that depletes thymocytes and establishes the cultured graft. Size matching between donor and recipient matters because the graft must fit the quadriceps bed and supply enough stroma for the child's body surface area, and the cultured slices are measured so that the manufacturing site can communicate the minimum-dose portion to the surgical team.生产始于从特定年龄范围的健康婴儿获取供体胸腺组织，这些婴儿接受过切除部分胸腺的心脏手术，且体型与预期受者接近。组织随后加工培养 13 至 20 天方可植入，该步骤清除胸腺细胞并建立培养移植物。供体与受者间的体型匹配很重要，因为移植物须适配股四头肌床并为患儿的体表面积提供足够基质，培养组织片经测量以使生产场所能向手术团队指明最小剂量部分。
• The formalin-treated absorbable gelatin sponge and fetal bovine serum in the product are not incidental excipients in the usual sense: the sponge provides the scaffold on which the thymic slices are arranged for implantation, and the composition is declared on the label so that surgical teams and regulators can see exactly what enters the muscle. The porcine skin gelatin component serves a similar structural role in the implanted construct. For a product whose active principle is living tissue, the formulation question is how to keep that tissue viable and correctly positioned during implantation, and the answer in Rethymic's case is a surgical matrix rather than a pharmaceutical dosage form. Stability is managed through the 13-to-20-day culture window and the requirement for a single surgical session at a qualified hospital.产品中的甲醛处理可吸收明胶海绵与胎牛血清并非通常意义上的普通辅料：海绵为胸腺组织片的植入排列提供支架，组成在标签上声明，使手术团队与监管机构能准确看到进入肌肉的物质。猪皮明胶成分在植入构造中起类似的结构作用。对活性原理为活组织的产品而言，处方问题是如何在植入期间保持组织存活且位置正确，Rethymic 的答案是手术基质而非药物剂型。稳定性通过 13 至 20 天的培养窗口及在合格医院单次手术的要求来管理。

Society and culture

• Rethymic occupies an unusual position in the pricing debate as a tissue-based therapy rather than a gene or cell therapy, with a wholesale acquisition cost reported at 2.81 million dollars in 2025. The company's counterweight is the cost of the untreated disease, with congenital athymia patients averaging 150 hospital days per year and an estimated 5.5 million dollars of supportive care over three years. The therapy is widely covered by insurance plans, and the product website notes that financial assistance programmes or charities may help uninsured or underinsured patients. The approval also carried a rare pediatric disease voucher, a transferable priority-review incentive created to reward development of treatments for rare childhood diseases.Rethymic 在定价争论中占据特殊位置，它是基于组织的疗法而非基因或细胞疗法，2025 年报告的批发采购价为 281 万美元。公司的制衡点是未治疗疾病的成本：先天性胸腺发育不全患者平均每年住院 150 天，估计三年支持治疗费用 550 万美元。该疗法被多数保险计划覆盖，产品网站指出经济援助计划或慈善机构或可帮助未参保及参保不足的患者。该批准还附带罕见儿科疾病券，一种可转让的优先审评激励，旨在奖励罕见儿童疾病治疗药物的开发。
• The product is frequently described as the world's first regenerative-tissue-based therapy, a framing that distinguishes it from the gene therapies with which it shares the top of the price table. Its story is told less in the media than those therapies because the disease it treats is ultra-rare, with an estimated 17 to 24 affected births per year in the United States, and because the patients are infants whose families engage with the therapy through specialist immunodeficiency centres rather than public campaigns. The patient-advocacy landscape is that of primary immunodeficiency generally, with organisations such as the Immune Deficiency Foundation providing the disease context that made the development programme possible.该产品常被描述为全球首个基于再生组织的疗法，这一框架将其与同踞价格表顶端的基因疗法区分开来。其故事的媒体曝光度低于那些疗法，因为所治疾病超罕见（美国估计每年仅 17 至 24 例受累新生儿），也因为患者是婴儿，其家庭通过专科免疫缺陷中心而非公众活动接触该疗法。患者倡导的版图是一般意义上的原发性免疫缺陷，免疫缺陷基金会等组织提供了使开发项目成为可能的疾病背景。
• The rare pediatric disease voucher awarded with the approval belongs to a wider policy experiment in using transferable incentives to pull development toward neglected diseases, and it sits alongside the orphan exclusivity that runs to 2028 as part of the product's reward structure. For the immunodeficiency community, the larger cultural significance is proof that a devastating ultra-rare immunodeficiency can be treated at its root rather than managed supportively, a message that has reshaped expectations for congenital immune disorders. The long development arc, from a Duke academic programme through a Basel-based specialty company to a Japanese pharmaceutical group, is itself a case study in how academic innovations in rare disease reach the market.获批时授予的罕见儿科疾病券属于更广泛的政策实验，即用可转让激励把开发拉向被忽视的疾病，它与至 2028 年的孤儿药独占期共同构成产品回报结构的一部分。对免疫缺陷学界而言，更大的文化意义在于证明一种毁灭性的超罕见免疫缺陷可从根源治疗而非仅作支持处理，这一信息重塑了对先天性免疫疾病的预期。漫长的发展弧线——从杜克学术项目经巴塞尔专科公司再到日本制药集团——本身就是学术罕见病创新如何进入市场的案例研究。

Availability and economics

• Rethymic is available only in the United States, where it is prescription-only, and it has no marketing authorization in any other jurisdiction. Orphan exclusivity runs to 8 October 2028, and no generic or biosimilar pathway applies to a surgically implanted allogeneic tissue. Access in practice is concentrated at the handful of qualified centres able to receive the cultured graft and perform the quadriceps implantation, with reporting in 2025 identifying Duke Children's Hospital as the only facility routinely performing the procedure, so geography remains a practical determinant of access.Rethymic 仅在美国供应，为处方药，在其他司法管辖区无上市许可。孤儿药独占期至 2028 年 10 月 8 日，手术植入的同种异体组织不适用仿制药或生物类似药路径。实践中的可及性集中于少数能够接收培养移植物并实施股四头肌植入的合格中心，2025 年报道指出杜克儿童医院是唯一常规开展该手术的机构，因此地理因素仍是可及性的实际决定因素。
• Because the Duke programme ran as a single-centre effort from 1993 to 2020, families of children with congenital athymia outside the United States have historically reached treatment through referral to that centre rather than through a licensed product in their own country, and no equivalent authorization exists elsewhere. Inside the United States, the bottleneck is not the label but the logistics: donor tissue of the right size, a 13-to-20-day culture window, a qualified surgical team and a quadriceps bed ready to receive the slices must converge on a single date. Sumitomo's stated priority of expanding sales therefore depends on widening the circle of qualified centres as much as on raising awareness of the disease, and the fiscal 2025 forecast of sales matching fiscal 2024 implies that expansion remains incremental.由于杜克项目自 1993 至 2020 年一直是单中心努力，美国以外先天性胸腺发育不全患儿的家庭历来通过转诊至该中心获得治疗，而非通过本国的许可产品，其他地方不存在同等授权。在美国国内，瓶颈不在标签而在后勤：合适尺寸的供体组织、13 至 20 天的培养窗口、合格外科团队与准备好接收组织片的股四头肌床必须在同一天汇合。住友制药扩大销售的既定优先事项因此既取决于提高疾病认知，也取决于扩大合格中心的圈子，而 2025 财年与 2024 财年持平的销售预测意味着扩张仍是渐进的。
• North American sales were reported at 45 million dollars for fiscal 2024, with a similar figure forecast for 2025, a modest return on a programme that took more than 25 years and overcame a manufacturing-related complete response letter. The economics are those of an ultra-rare therapy: a single price applied to a handful of patients per year, justified against the alternative of years of hospital-based supportive care. The rare pediatric disease voucher awarded at approval represents additional value that can be sold to another developer, a mechanism designed to reward exactly this kind of long, narrow development effort. For the field, Rethymic demonstrated that a tissue product can traverse the modern regulatory pathway from academic programme to licensed therapy.北美 2024 财年销售额报告为 4500 万美元，2025 年预测数字相近，对一个历时 25 年以上并克服生产相关完整回复函的项目而言回报有限。其经济性是超罕见疗法的经济性：单一价格适用于每年少数患者，其合理性对照的是多年住院支持治疗的替代方案。获批时授予的罕见儿科疾病券代表可出售给其他开发者的额外价值，该机制旨在奖励的正是这类漫长而狭窄的开发努力。对该领域而言，Rethymic 证明了组织产品能从学术项目走通现代监管路径直至获批上市。